Dermapharm Holding SE Continues Growth in Q2 2025

Dermapharm Holding SE maintains its projected growth trajectory in the second quarter of 2025. The company confirms its full-year guidance for 2025, forecasting consolidated revenue of EUR 1,160–1,200 million and an increase in adjusted EBITDA to EUR 322–332 million. Despite a slight year-on-year decline in both consolidated revenue and adjusted EBITDA, the figures still stand at EUR 574.5 million and EUR 148.0 million respectively, with an adjusted EBITDA margin of 25.8%.

The "Branded pharmaceuticals" segment notably offset declines in the parallel import business and Arkopharma. Adjusted EBITDA grew by 3.7% compared to the prior-year quarter, highlighting the success of Dermapharm's strategic initiatives.

The "Other healthcare products" segment reported growth driven by B2B business development at Euromed, although foreign exchange losses impacted earnings. Arkopharma performed solidly, bolstering the company's long-term business model.